## Swiss Medical Weekly

Formerly: Schweizerische Medizinische Wochenschrift An open access, online journal • www.smw.ch

Errata | Published 04 November 2021 | doi:10.4414/SMW.2021.w30104 Cite this as: Swiss Med Wkly. 2021;151:w30104

## Erratum to: Management of transthyretin amyloidosis

Erratum to Swiss Med Wkly. 2021;151:w30053 (DOI 10.4414/smw.2021.w30053)

The published manuscript contained a typing error in the chapter "Wild-type transthyretin amyloidosis (ATTR-wt)", subchapter "Treatment" (page 13 of the PDF version). It reads: Treatment with tafamidis 61 mg should be considered for patients with cardiac ATTRwt amyloidosis and dyspnea NYHA I-II. [IIa, B].

The correct wording is: Treatment with tafamidis 61 mg should be considered for patients with cardiac ATTRwt amyloidosis and dyspnea NYHA I-III. [IIa, B].

The error occured during manuscript editing and is not in the authors responsability. It has now been corrected online. We apologize to the authors and readers for this error.